Picture of Fortis Frontier logo

FORF — Fortis Frontier News Story

0.000.00%
gb flag iconLast trade - 00:00
FinancialsHighly SpeculativeMicro Cap

Phlebotomy tests registered in the UK and EU

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250114:nRSN1362Ta&default-theme=true

RNS Number : 1362T  MyHealthChecked PLC  14 January 2025

 

MyHealthChecked PLC

("MyHealthChecked" or the "Company")

 

Phlebotomy tests registered in the UK and EU

 

MyHealthChecked PLC (AIM: MHC), the consumer home-testing healthcare
company, announces that the Company's phlebotomy test kits have been
registered in the UK and EU. This is a key step in enabling MyHealthChecked to
launch and commercialise its phlebotomy service.

 

The phlebotomy tests will need to be carried out by a trained phlebotomist and
MyHealthChecked is looking to commercialise this service in H1 2025. The
phlebotomy test kits will be in addition to the Company's existing range of
at-home and rapid tests, including DNA and blood sample collection kits.

 

Penny McCormick, CEO of MyHealthChecked plc, commented: "Registration of our
phlebotomy tests in the UK and EU is a great achievement for the team and
brings us one step closer to commercialising our phlebotomy tests. We are on
track to launch our phlebotomy service in the first half of 2025 and look
forward to providing an update to shareholders in due course."

 

For further information contact:

 

 MyHealthChecked plc                www.myhealthchecked.com (http://www.myhealthchecked.com/)
 Penny McCormick, Chief Executive Officer                                         via Walbrook PR

 SPARK Advisory Partners Limited (NOMAD)                                          Tel: +44 (0)20 3368 3550
 Neil Baldwin / Jade Bayat

 Dowgate Capital Limited (Broker)   Tel: +44 (0)20 3903 7715
 David Poutney / Nicholas Chambers

 Walbrook PR Ltd (Media & IR)       Tel: +44 (0)20 7933 8780 or myhealthcheckedplc@walbrookpr.com
                                    (mailto:myhealthcheckedplc@walbrookpr.com)
 Paul McManus / Alice Woodings      Mob: +44 (0)7980 541 893 / +44(0)7407 804 654

 

 

About MyHealthChecked PLC (www.myhealthcheckedplc.com
(http://www.myhealthcheckedplc.com/) )

 

MyHealthChecked PLC, based in Cardiff, is an AIM-quoted pioneering UK
healthcare company focused on a range of at-home healthcare and wellness
tests.

 

MyHealthChecked (http://www.myhealthchecked.com/)  is the umbrella brand of a
range of at-home rapid tests, as well as DNA, RNA and blood sample collection
kits which have been created to support customers on their journeys to
wellness. The tests are lateral-flow self-tests, whilst the sample collection
kits enable the collection of blood, urine, nasal or mouth swab samples that
are analysed in partner laboratories for a range of biomarkers. The tests have
been made available online and for over-the-counter purchase.

 

The MyHealthChecked portfolio has been identified as part of a change in
mindset as customers become more familiar with the concept of accessible
healthcare in the growing at home testing kit market with a focus on
accessibility at the right price, led by UK-based experts.

 

About Reach announcements

Reach is an investor communication service aimed at assisting listed and
unlisted (including AIM quoted) companies to distribute media only /
non-regulatory news releases such as marketing messages, corporate and product
information into the public domain. An RNS Regulatory announcement is required
to be notified under the AIM Rules for Companies.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRASFLFIDEISELF

Recent news on Fortis Frontier

See all news